Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Blood

• Publication date

  2013-07-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/blood-2013-02-483750PMID 23704092
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML.

  2013cited by this paper
• Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials

  2012cited by this paper
• BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management.

  2012cited by this paper
• Discontinuation of Second Generation (2G) Tyrosine Kinase Inhibitors (TKI) in Chronic Phase (CP)-Chronic Myeloid Leukemia (CML) Patients with Stable Undetectable BCR-ABL Transcripts

  2012cited by this paper
• Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response.

  2012cited by this paper
• Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.

  2011cited by this paper
• Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay

  2011cited by this paper
• Minimal residual disease and discontinuation of therapy in chronic myeloid leukemia: can we aim at a cure?

  2011cited by this paper
• Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia

  2011cited by this paper
• Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease features

  2011cited by this paper
• Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia.

  2010cited by this paper
• Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR

  2010influential reference
• Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.

  2010cited by this paper
• In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib.

  2010cited by this paper
• Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.

  2009cited by this paper
• Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells

  2009cited by this paper
• Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy.

  2009cited by this paper
• Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha

  2008cited by this paper
• molecule Beyond the increasing complexity of the immunomodulatory HLA-G

  2008cited by this paper
• BCR-ABL Messenger RNA Levels Continue to Decline in Patients with Chronic Phase Chronic Myeloid Leukemia Treated with Imatinib for More Than 5 Years and Approximately Half of All First-Line Treated Patients Have Stable Undetectable BCR-ABL Using Strict Sensitivity Criteria

  2007cited by this paper
• Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.

  2007cited by this paper
• Diagnosis and monitoring of chronic myeloid leukemia by qualitative and quantitative RT-PCR.

  2006cited by this paper
• Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications

  2006cited by this paper
• Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy.

  2006cited by this paper
• Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter?

  2006cited by this paper
• Dynamics of chronic myeloid leukaemia

  2005cited by this paper
• Durability of molecular remission in chronic myeloid leukemia patients treated with imatinib vs allogeneic stem cell transplantation

  2005cited by this paper
• Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program

  2003cited by this paper
• Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia.

  2003cited by this paper
• Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.

  2003cited by this paper
• Interferon-α, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia

  2003cited by this paper
• Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa.

  2002cited by this paper
• Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia

  2000cited by this paper
• Mobilization of predominantly Philadelphia chromosome‐negative blood progenitors using cyclophosphamide and rHUG‐CSF in early chronic‐phase chronic myeloid leukaemia: correlation with Sokal prognostic index and haematological control

  1997cited by this paper
• Which compartments are involved in Philadelphia‐chromosome positive chronic myeloid leukaemia? An answer at the single cell level by combining May‐Grünwald‐Giemsa staining and fluorescence in situ hybridization techniques

  1997cited by this paper
• Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients.

  1995cited by this paper

• Toward the future management of patients with CML and Ph + ALL: real-world safety insights from dasatinib pharmacovigilance

  2026cites this paper
• Evolving Therapeutic Algorithms in Chronic Myeloid Leukemia: Integrating Efficacy, Safety, and Survivorship.

  2026cites this paper
• Second attempt to discontinue TKI after molecular relapse in patients with chronic myeloid leukemia: A real‐life Italian multicenter study

  2026cites this paper
• Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX)

  2026cites this paper
• 慢性髓性白血病患者停用酪氨酸激酶抑制剂后停药综合征和心理问题的发生及其影响因素

  2025cites this paper
• Insights into Treatment-Free Remission (TFR) outcomes in Chronic Myeloid Leukaemia (CML) – a tertiary centre experience in Malaysia

  2025cites this paper
• Distribution of BCR::ABL1 transcript types and response to therapy in pediatric patients with chronic myeloid leukemia.

  2025cites this paper
• Bosutinib for Successful Treatment‐Free Remission in Chronic Myeloid Leukemia

  2025cites this paper
• Challenges determining the best target duration of deep molecular response after which to attempt achieving therapy-free remission in chronic myeloid leukaemia

  2025cites this paper
• Successful Lung Transplantation in A Patient With Pre-Existing Chronic Myeloid Leukemia Treated With Imatinib: A Case Report.

  2025cites this paper
• Clinical applicability of the ELN2020 criteria for tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia: insights from a multicenter retrospective study in real-world practice.

  2025cites this paper
• Investigating Breakpoint Cluster Region-Abelson 1(BCR-ABL) (BCRABL1) signal patterns across chronic myeloid leukemia morphologic phases and its impact on molecular response

  2025cites this paper
• Treatment‐Free Remission in Chronic Myeloid Leukemia: Revisiting the “W” Questions

  2025cites this paper
• Treatment free remission (TFR) in chronic myeloid leukemia—results, compliance and patterns of failure from a tertiary care cancer centre in India

  2025cites this paper
• Eligibility for treatment-free remission among chronic myeloid leukemia patients in Iraqi Kurdistan region

  2025cites this paper
• Lipid Storage and Therapy Resistance in Chronic Myeloid Leukaemia: A Novel Perspective on Targeting Metabolic Vulnerabilities

  2025cites this paper
• Immune Surveillance in Chronic Myeloid Leukemia: Tumor Antigen Expression and CD8+ T Cell Function in the Context of Treatment- Free Remission

  2025cites this paper
• Treatment‐free remission in chronic myeloid leukaemia patients with accelerated phase or tyrosine kinase inhibitor therapy failure

  2025cites this paper
• 影响儿童及青少年慢性髓性白血病患者停用伊马替尼后无治疗缓解结局的相关因素分析

  2025cites this paper
• Multimodal gene and targeted drug therapy for chronic myelogenous leukemia: Computational target analysis and therapeutic validation

  2025cites this paper
• The PD1 Molecule May Contribute to Lower Treatment-Free Remission Rates in Patients with Chronic Myeloid Leukemia with the e13a2 Transcript

  2025cites this paper
• Precision Medicine in Myeloid Neoplasia: Challenges and Opportunities

  2025cites this paper
• Clinical and biological predictors of treatment-free remission in CML

  2025cites this paper
• [Guideline for the diagnosis and treatment of chronic myeloid leukemia in China (2025)].

  2025cites this paper
• Real-World Evidence of Treatment-Free Remission Strategies and Outcomes in Chronic Myeloid Leukemia

  2025cites this paper
• Treatment Cessation in Chronic Myeloid Leukemia: Evidence and Uncertainties

  2025cites this paper
• Treatment Free Remission (TFR) in Chronic Phase‐Chronic Myeloid Leukemia (CP‐CML): Analysis of Predictive Factors and Novel Baseline Scoring System to Predict Molecular Relapse

  2025cites this paper
• Management of chronic myeloid leukemia in 2025

  2025cites this paper
• PAI-1, hematopoietic stem cell, and chronic myeloid leukemia

  2025cites this paper
• Flow cytometric detection of BCR::ABL1 in T-lymphocytes in chronic myeloid leukaemia.

  2025cites this paper
• The Evolution of Treatment-Free Remission.

  2025cites this paper
• Chronic inflammation deters natural killer cell fitness and cytotoxicity in myeloid leukemia

  2024cites this paper
• IFN‐α treatment may enable discontinuation of TKIs in NK cell‐licensed patients with CML‐CP

  2024cites this paper
• Discontinuation of Tyrosine Kinase Inhibitor Therapy and Treatment Free Remission (TFR) in Chronic Myeloid Leukemia: Successful Achievement of TFR in More Than Two-Third of Patients in a Real-World Practice.

  2024cites this paper
• Treatment-free remission after discontinuation of tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: a systematic review and meta-analysis

  2024influential citation
• Chiglitazar diminishes the warburg effect through PPARγ/mTOR/PKM2 and increases the sensitivity of imatinib in chronic myeloid leukemia

  2024cites this paper
• Sudden Blast Crisis in a Chronic Myeloid Leukemia Patient in Treatment-Free Remission: A Case Report and Literature Review

  2024cites this paper
• Treatment‐free remission as a new goal in the management of chronic myeloid leukemia: Clinical and biological aspects

  2024cites this paper
• Treatment free remission (TFR) after second-generation tyrosine kinase inhibitors (2G-TKIs) treatment in chronic myeloid leukemia (CML): from feasibility to safety

  2024cites this paper
• Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trial

  2024cites this paper
• Lysosomal acid lipase A modulates leukemia stem cell response to venetoclax/tyrosine kinase inhibitor combination therapy in blast phase chronic myeloid leukemia

  2024cites this paper
• Efficacy and safety of flumatinib in the treatment of newly diagnosed chronic myeloid leukemia in the chronic phase: A real-world single-center retrospective study, with a focus on premature drug discontinuation.

  2024cites this paper
• Treatment-Free Remission in Chronic Myeloid Leukemia

  2024cites this paper
• High Level of CD8+PD-1+ Cells in Patients with Chronic Myeloid Leukemia Who Experienced Loss of MMR after Imatinib Discontinuation

  2024cites this paper
• 25 years of experience in the treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: results, opportunities, questions

  2024cites this paper
• Activating p53 abolishes self-renewal of quiescent leukaemic stem cells in residual CML disease

  2024cites this paper
• Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era – analysis of the European LeukemiaNet Blast Phase Registry

  2024cites this paper
• Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Strategies to Optimize Success and New Directions

  2024cites this paper
• State-transition modeling of blood transcriptome predicts disease evolution and treatment response in chronic myeloid leukemia

  2024cites this paper
• An era of immunosuppressant withdrawal in systemic lupus erythematosus: winning through weaning.

  2024cites this paper
• Computational modeling reveals key factors driving treatment-free remission in chronic myeloid leukemia patients

  2024cites this paper
• Philadelphia chromosome-positive B cell acute lymphoblastic phase arising 24 years after treatment-free remission for chronic myeloid leukemia with identical BCR-ABL fusion transcript

  2024cites this paper
• KIR3DL1-HLA-Bw status in CML is associated with achievement of TFR: the POKSTIC trial, a multicenter observational study

  2024cites this paper
• Kinetics of BCR::ABL1 transcript levels and molecular relapse after tyrosine kinase inhibitors discontinuation in chronic myeloid leukemia patients: preliminary results from the DES-CML study

  2024cites this paper
• Nilotinib vs dasatinib in achieving MR4.5 for de novo chronic myeloid leukemia: the randomized JALSG CML212 study

  2024cites this paper
• Dynamics and bifurcations in a model of chronic myeloid leukemia with optimal immune response windows

  2024cites this paper
• Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring

  2024cites this paper
• Treatment-free remission after discontinuation of imatinib, dasatinib, and nilotinib in patients with chronic myeloid leukemia

  2023influential citation
• SOHO State of the Art Updates and Next Questions | Update on Treatment-Free Remission in Chronic Myeloid Leukemia (CML).

  2023cites this paper
• 儿童慢性髓性白血病酪氨酸激酶抑制剂停药的研究进展

  2023cites this paper
• Chronic Myeloid Leukemia, from Pathophysiology to Treatment-Free Remission: A Narrative Literature Review

  2023cites this paper
• Dose optimization strategy of the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib for chronic myeloid leukemia: From clinical trials to real-life settings

  2023cites this paper
• Comprehensive analysis of the immune pattern of T cell subsets in chronic myeloid leukemia before and after TKI treatment

  2023cites this paper
• Treatment free remission in pediatric chronic myeloid leukemia

  2023cites this paper
• Sudden lymphoid blast crisis after tyrosine kinase inhibitor discontinuation in chronic phase chronic myeloid leukemia: cautionary tales for appropriate molecular monitoring

  2023cites this paper
• Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis

  2023cites this paper
• Mathematical modeling of regulatory networks of intracellular processes – Aims and selected methods

  2023cites this paper
• Management of chronic myeloid leukaemia: current treatment options, challenges, and future strategies

  2023cites this paper
• How to improve treatment‐free remission eligibility in chronic myeloid leukaemia?

  2023cites this paper
• Second Treatment-Free Remission Attempt in Patients with Chronic Myeloid Leukemia.

  2023cites this paper
• Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid Leukemia

  2023cites this paper
• Exploration of treatment‐free remission in CML, based on molecular monitoring

  2023cites this paper
• Long-term Results of Imatinib Discontinuation in Patients with Chronic-phase Chronic Myeloid Leukemia: A National Multicenter Prospective Study

  2023cites this paper
• Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation

  2023cites this paper
• Effect of BCR::ABL1 transcript type and droplet digital polymerase chain reaction on successful treatment-free remission in chronic myeloid leukemia patients who discontinued tyrosine kinase inhibitor

  2023cites this paper
• Overcoming BCR::ABL1 dependent and independent survival mechanisms in chronic myeloid leukaemia using a multi-kinase targeting approach

  2023cites this paper
• Risk of progression in chronic phase‐chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR‐PRO study

  2023cites this paper
• How should we interpret conclusions of TKI-stopping studies

  2023cites this paper
• A Deeply Quiescent Subset of CML LSC Depend on FAO Yet Avoid Deleterious ROS by Suppressing Mitochondrial Complex I.

  2023cites this paper
• Myelofibrosis at diagnosis is associated with the failure of treatment-free remission in CML patients

  2023cites this paper
• Lineage-specific detection of residual disease predicts relapse in chronic myeloid leukemia patients stopping therapy.

  2023cites this paper
• State-transition Modeling of Blood Transcriptome Predicts Disease Evolution and Treatment Response in Chronic Myeloid Leukemia

  2023cites this paper
• Long-term outcomes of frontline imatinib therapy for chronic myeloid leukemia in China

  2023cites this paper
• A Real-World Evidence-Based Study of Long-Term Tyrosine Kinase Inhibitors Dose Reduction or Discontinuation in Patients with Chronic Myeloid Leukaemia

  2023cites this paper
• Molecular BCR::ABL1 Quantification and ABL1 Mutation Detection as Essential Tools for the Clinical Management of Chronic Myeloid Leukemia Patients: Results from a Brazilian Single-Center Study

  2023cites this paper
• Identification of multivariable microRNA and clinical biomarker panels to predict imatinib response in chronic myeloid leukemia at diagnosis

  2023cites this paper
• Peripheral lymphocyte subsets as predicting factors for molecular recurrence after imatinib discontinuation in a phase 2 imatinib discontinuation trial in patients with chronic myeloid leukemia

  2023cites this paper
• Continuous therapy response references for BCR::ABL1 monitoring in pediatric chronic myeloid leukemia

  2023cites this paper
• The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib

  2023cites this paper
• Management of TKI-resistant chronic phase CML.

  2022cites this paper
• A Study to Explore the Role of IDH1 (R132) Mutation on Imatinib Toxicity and Effect of ABCG2/OCT1 Expression on N-Desmethyl Imatinib Plasma Level in Egyptian Chronic Myeloid Leukemia Patients

  2022cites this paper
• 中国真实世界慢性髓性白血病患者停用酪氨酸激酶抑制剂的观察研究

  2022cites this paper
• Current childhood chronic myeloid leukemia management under tyrosine kinase inhibitor treatment

  2022cites this paper
• Alterations in cellular metabolisms after TKI therapy for Philadelphia chromosome-positive leukemia in children: A review

  2022cites this paper
• OTT_A_371847 1123..1141

  2022cites this paper
• Molecular skin cancer diagnosis: Promise and limitations.

  2022cites this paper
• [Withdrawal syndrome after tyrosine kinase inhibitors discontinuation in patients with chronic myeloid leukemia].

  2022cites this paper
• Molecular Changes in Chronic Myeloid Leukemia During Tyrosine Kinase Inhibitors Treatment. Focus on Immunological Pathways

  2022cites this paper
• Observation in a treatment-free remission in chronic myeloid leukemia patients with a stable deep molecular response in the Russian portion of the international multicenter population based study EUTOS PBS

  2022cites this paper
• Deep molecular response in patients with chronic phase chronic myeloid leukemia treated with the plasminogen activator inhibitor‐1 inhibitor TM5614 combined with a tyrosine kinase inhibitor

  2022cites this paper